8-K: Helius Medical Technologies Regains Nasdaq Compliance After $8.1 Million Public Offering

Helius Medical Technologies, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent public offering that raised approximately $8.1 million.

Summary

• Helius Medical Technologies, Inc. (the "Company") received a written notice from Nasdaq on March 31, 2025, indicating non-compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), as its stockholders' equity had fallen below $2.5 million.
• On April 1, 2025, Nasdaq granted the Company an extension until June 30, 2025, to regain compliance with the listing rules.
• The Company completed a public offering on June 6, 2025, which generated net proceeds of approximately $8.1 million.
• As of June 17, 2025, an unaudited interim consolidated balance sheet shows the Company's stockholders' equity at $6,561,000, exceeding the $2.5 million minimum requirement.
• The Company believes it now satisfies the Stockholders Equity Requirement and is awaiting formal confirmation from Nasdaq regarding its continued listing.

Sentiment

Score: 7

Explanation: The company successfully addressed a critical delisting threat by raising capital and regaining Nasdaq compliance, which is a significant positive. However, the underlying financial weakness that necessitated the capital raise and the resulting shareholder dilution temper the overall sentiment.

Positives

• Successfully regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million.
• Completed a public offering that raised approximately $8.1 million in net proceeds, significantly bolstering the Company's equity.
• Stockholders' equity increased to $6,561,000 as of June 17, 2025, well above the required threshold.

Negatives

• The Company previously failed to meet Nasdaq's minimum stockholders' equity requirement, leading to a non-compliance notice.
• The need for a public offering to regain compliance indicates prior financial weakness and resulted in dilution for existing shareholders.

Risks

• The Company is awaiting Nasdaq's formal confirmation of compliance with the Stockholders Equity Rule and all other applicable criteria for continued listing.
• The unaudited interim consolidated balance sheet is subject to potential adjustments by the Company or its independent registered public accounting firm upon audit or review.

Future Outlook

The Company believes it has satisfied the Nasdaq Stockholders Equity Requirement and is currently awaiting formal confirmation from Nasdaq regarding its continued listing. The unaudited balance sheet provided may be subject to adjustments following a full audit or review.

Management Comments

• "The Company believes it satisfies Stockholders Equity Requirement."

Industry Context

This announcement primarily addresses a specific regulatory compliance issue for Helius Medical Technologies, Inc. and does not provide broader insights into industry trends or competitive dynamics within the medical technology sector. It reflects a company's effort to maintain its public listing status rather than an operational or strategic update relevant to the wider industry.

Stakeholder Impact

• Shareholders: Positive impact due to the prevention of delisting and maintenance of liquidity on Nasdaq. Negative impact due to dilution from the public offering.
• Creditors: Improved financial stability and balance sheet strength due to increased stockholders' equity, potentially reducing perceived credit risk.

Next Steps

• Await Nasdaq's formal confirmation that the Company has evidenced compliance with the Stockholders Equity Rule and all other applicable criteria for continued listing on The Nasdaq Capital Market.

Key Dates

Recommendation

Keywords

Helius Medical Technologies, HSDT, Nasdaq compliance, public offering, stockholders equity, SEC filing, Form 8-K, listing requirements, capital raise, financial reporting